Voclosporin in Lupus Nephritis

Secondary GNmedium

A 33-year-old woman with active Class III lupus nephritis and eGFR 75 mL/min/1.73 m2 is being treated. Her nephrologist asks about voclosporin. According to KDIGO 2024, what is the role of voclosporin in lupus nephritis?

  1. A.Voclosporin is recommended as effective first-line monotherapy for all patients
  2. B.Voclosporin is added as a calcineurin inhibitor to mycophenolate and glucocorticoidsCorrect
  3. C.Voclosporin is reserved only for refractory disease after several prior treatment failures
  4. D.Voclosporin is not recommended because it lacks supporting trial evidence

Explanation

Voclosporin is a next-generation calcineurin inhibitor shown in the AURORA-1 trial (and durable in AURORA-2) to increase complete renal response when added to a mycophenolic acid analog plus low-dose glucocorticoids. KDIGO 2024 includes voclosporin as a CNI option in multitarget (triple) therapy, generally in patients with eGFR above about 45 mL/min/1.73 m2. It is not monotherapy, is not restricted to refractory disease, and is evidence-supported. A fixed-dose regimen without drug-level monitoring is a practical advantage, but blood pressure and eGFR must be tracked.

Why each option

A.
Voclosporin is an add-on to background therapy, not monotherapy.
B.
Correct: voclosporin is an add-on CNI in multitarget therapy with MMF plus glucocorticoids (AURORA trials).
C.
It is used as initial add-on therapy, not only for refractory disease.
D.
AURORA-1/AURORA-2 provide strong evidence for voclosporin efficacy.

Reference: KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis, Kidney Int 2024;105(1S):S1-S69; Rovin BH et al. (AURORA-1). Lancet 2021;397:2070-2080.

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

More Secondary GN questions

Browse other topics